Atossa Genetics (ATOS) Reports Q2 Loss of $0.11

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. SPCX
9. WDC
10. QGEN

Go back to Atossa Genetics (ATOS) Reports Q2 Loss of $0.11

Atossa Genetics Announces Second Quarter 2015 Financial Results and Provides Company Update; Achieves Total Revenue for Q2 2015 of $2.7 Million

August 6, 2015 4:02 PM EDT

SEATTLE, WA -- (Marketwired) -- 08/06/15 -- Atossa Genetics Inc. (NASDAQ: ATOS) today announced second quarter 2015 financial results and provided an update on recent company developments.

Dr. Steven C. Quay, Chairman, CEO & President, commented, "We are highly encouraged by our second quarter performance with record revenues for our Pharmacogenomics tests and our acquisition of the rights to Besins Healthcare's Afimoxifene Gel, which we are developing for the potential treatment of hyperplasia of the breast. We've made great advancements towards achieving our goals for 2015 and we look forward to continued progress towards initiating clinical trials... More